Review





Similar Products

94
Hycult Biotech anti tlr2 mab t2 5
Pneumococcal challenge in human CSF generated higher release of LDH, IL-6 and IL-8 by Ben-Men-1 cells. Ben-Men-1 cells were challenged with increasing concentrations of SP D39 (0.25/0.5/1/2x10 7 CFU/ml) while being held in human CSF from 8 different donors (n=3-6, control: MCM) for 24h. Negative control was pure bacterial THY growth medium. Supernatants were analyzed for LDH (positive control: triton 1%), IL-6 and IL-8 (A, C) . (B) = Summary of data from (A–C) . During pneumococcal challenge (2x10 7 CFU/ml, MCM, negative controls: THY medium, PBS), cells were treated with the following inhibitors: TLR-cocktail <t>(25µg/ml</t> <t>anti-TLR2</t> antibody + 5µM TLR4 inhibitor + 20µg/ml chloroquine), 0.1-10 µM BAY 11-7082, 0.01-1µM 666-15, 0.01-1µM JQ1 or DMSO control. (D) Supernatants were analyzed for LDH and IL-6. Data are given as individual values as well as means ± SD.
Anti Tlr2 Mab T2 5, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tlr2+mab/TLR2%2C+Mouse%2FHuman%2C+mAb+T2%2E5/pmc13215843-69-8-12
Average 94 stars, based on 1 article reviews
anti tlr2 mab t2 5 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
InvivoGen mab mtlr2 anti mouse human tlr2
<t>TLR2</t> is required for MutuDC sensing of, but not internalization of MRSA (A) Relative pHrodo labeled MRSA internalization by MutuDC over 4 h following stimulation with DapS A8819 (light blue symbols) or DapR A8817 (dark blue symbols), or media alone (white squares). Prior to stimulation, MutuDC were pre-treated for 1 h with <t>TLR2</t> blocking antibody (clone T2.5; triangles with dashed lines) or media alone (circles with filled lines). Relative MRSA internalization by each DC subset is expressed as the gMFI of pHrodo. Results show the mean and (SD) of duplicates from one experiment, representative of two independent experiments. (B) Cytokine secretion (pg/mL) by MutuDC stimulated with <t>TLR2</t> ligand peptidoglycan of S. aureus (PGN-SA) (10 μg/mL) or (C) DapS (A8819; light blue) or DapR (A8817; dark blue) MRSA (MOI of 10) for 18 h. MutuDC were first pre-treated with either <t>TLR2</t> blocking antibody (dot-filled bars) or media alone (filled bars) as in A, or an isotype control (clone 163D3, empty bars) at 1 μg/mL. Results pooled from four (B) or three (C) independent experiments and expressed as the mean ± SEM, with each symbol (circle, square, and directional triangles) representing paired experimental replicates ( n = 3). Statistical significance determined using paired t test and reported as indicated by an ∗ when p ≤ 0.05. (D) Expression of surface activation markers by MutuDC stimulated with DapS A8819 MRSA. DC were pre-treated with TLR2 blocking antibody (black trace), isotype control (dashed red trace), and media alone (light blue shaded). Unstained control sample is shown for each marker (black dashed trace). Data shown from one experiment, representative of three independent experiments.
Mab Mtlr2 Anti Mouse Human Tlr2, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tlr2+mab/MAb-mTLR2/pmc13186032-18-0-5
Average 96 stars, based on 1 article reviews
mab mtlr2 anti mouse human tlr2 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
InvivoGen anti human tlr2 mab anti tlr2
<t>TLR2</t> is required for MutuDC sensing of, but not internalization of MRSA (A) Relative pHrodo labeled MRSA internalization by MutuDC over 4 h following stimulation with DapS A8819 (light blue symbols) or DapR A8817 (dark blue symbols), or media alone (white squares). Prior to stimulation, MutuDC were pre-treated for 1 h with <t>TLR2</t> blocking antibody (clone T2.5; triangles with dashed lines) or media alone (circles with filled lines). Relative MRSA internalization by each DC subset is expressed as the gMFI of pHrodo. Results show the mean and (SD) of duplicates from one experiment, representative of two independent experiments. (B) Cytokine secretion (pg/mL) by MutuDC stimulated with <t>TLR2</t> ligand peptidoglycan of S. aureus (PGN-SA) (10 μg/mL) or (C) DapS (A8819; light blue) or DapR (A8817; dark blue) MRSA (MOI of 10) for 18 h. MutuDC were first pre-treated with either <t>TLR2</t> blocking antibody (dot-filled bars) or media alone (filled bars) as in A, or an isotype control (clone 163D3, empty bars) at 1 μg/mL. Results pooled from four (B) or three (C) independent experiments and expressed as the mean ± SEM, with each symbol (circle, square, and directional triangles) representing paired experimental replicates ( n = 3). Statistical significance determined using paired t test and reported as indicated by an ∗ when p ≤ 0.05. (D) Expression of surface activation markers by MutuDC stimulated with DapS A8819 MRSA. DC were pre-treated with TLR2 blocking antibody (black trace), isotype control (dashed red trace), and media alone (light blue shaded). Unstained control sample is shown for each marker (black dashed trace). Data shown from one experiment, representative of three independent experiments.
Anti Human Tlr2 Mab Anti Tlr2, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tlr2+mab/Anti-hTLR2-IgA/10__1007_slash_s13206___025___00226___x-336-8-12
Average 96 stars, based on 1 article reviews
anti human tlr2 mab anti tlr2 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

95
Miltenyi Biotec anti tlr2 monoclonal antibody mab
<t>TLR2</t> is required for MutuDC sensing of, but not internalization of MRSA (A) Relative pHrodo labeled MRSA internalization by MutuDC over 4 h following stimulation with DapS A8819 (light blue symbols) or DapR A8817 (dark blue symbols), or media alone (white squares). Prior to stimulation, MutuDC were pre-treated for 1 h with <t>TLR2</t> blocking antibody (clone T2.5; triangles with dashed lines) or media alone (circles with filled lines). Relative MRSA internalization by each DC subset is expressed as the gMFI of pHrodo. Results show the mean and (SD) of duplicates from one experiment, representative of two independent experiments. (B) Cytokine secretion (pg/mL) by MutuDC stimulated with <t>TLR2</t> ligand peptidoglycan of S. aureus (PGN-SA) (10 μg/mL) or (C) DapS (A8819; light blue) or DapR (A8817; dark blue) MRSA (MOI of 10) for 18 h. MutuDC were first pre-treated with either <t>TLR2</t> blocking antibody (dot-filled bars) or media alone (filled bars) as in A, or an isotype control (clone 163D3, empty bars) at 1 μg/mL. Results pooled from four (B) or three (C) independent experiments and expressed as the mean ± SEM, with each symbol (circle, square, and directional triangles) representing paired experimental replicates ( n = 3). Statistical significance determined using paired t test and reported as indicated by an ∗ when p ≤ 0.05. (D) Expression of surface activation markers by MutuDC stimulated with DapS A8819 MRSA. DC were pre-treated with TLR2 blocking antibody (black trace), isotype control (dashed red trace), and media alone (light blue shaded). Unstained control sample is shown for each marker (black dashed trace). Data shown from one experiment, representative of three independent experiments.
Anti Tlr2 Monoclonal Antibody Mab, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tlr2+mab/CD282+(TLR2)+Antibody%2C+anti-human%2Fmouse%2C+REAfinity/pmc11830813-61-5-17
Average 95 stars, based on 1 article reviews
anti tlr2 monoclonal antibody mab - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc anti human tlr2
Fig. 1. <t>TLR2</t> knockout reduces tau pathology and alleviates cognitive functions in rTg4510 mice. (A) Differential RNA expression of TLRs in AD brains compared to cognitively normal controls. Log2 fold changes are indicated. ACC, anterior cingulate cortex; CBE, cerebellum; DLPFC, dorsolateral prefrontal cortex; FP, frontal pole; IFG, inferior frontal gyrus; PCC, posterior cingulate cortex; PHG, parahippocampal gyrus; STG, superior temporal gyrus; TCX, temporal cortex. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. (B-D) Tlr2 KO ameliorates cognitive impairment in rTg4510 mice. The 6-month-old mice (tTA/WT, tTA/Tlr2 KO, rTg4510/ WT, rTg4510/Tlr2 KO) were analyzed with the Y-maze test [B, two-way ANOVA with Tukey test, n (male, female) = 10 (7, 3); 10 (2, 8); 8 (6, 2); 11 (4, 7)], novel object recognition test [C, two-way ANOVA with Tukey test, n (male, female) = 8 (5, 3); 7 (2, 5); 6 (4, 2); 7 (2, 5)], and passive avoidance test [D, paired t-test, n (male, female) = 10 (7, 3); 10 (2, 8); 9 (6, 3); 11 (4, 7)]. (E-G) Tlr2 KO reduces tau pathology and microglial activation in rTg4510 mice. Immunohistochemistry of AT8 and Iba1 in the frontal cortex, dentate gyrus, and entorhinal cortex (E). Scale bar, 20 μm. Quantification of AT8 signal intensities (F) and the number of Iba1- positive cells (G). Two-way ANOVA with Tukey test, n = 7, 6, 3, 5. Data are represented as mean ± SEM. N.S., not significant.
Anti Human Tlr2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tlr2+mab/Toll-like+Receptor+2+Rabbit+mAb/pm39098437-55-12-14
Average 95 stars, based on 1 article reviews
anti human tlr2 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

94
Hycult Biotech anti tlr2 t2 5 antibody
Figure 1. Strong pneumococcal meningitis phenotypes of <t>3d/Tlr2/4–/–</t> and Myd88–/– mice are largely indistinguish- able. (A–D) Pneumococcal meningitis was elicited by intracisternal injection of 1 × 105 CFU viable Streptococcus pneumoniae. Eighteen hours postinfection (p.i.), mice of the indicated genotypes (WT, n = 18; <t>Tlr2/4–/–,</t> n = 10; 3d/ <t>Tlr2/4–/–,</t> n = 10; Myd88–/–, n = 9; negative control with PBS, n = 8) were analyzed. After clinical examination (including the collection of clinical score values), CSF was obtained to determine leukocyte counts (A). Subsequently, the mice were sacrificed, and cerebellum (B) and blood (C) samples were collected for bacterial titer determinations. (D) Clinical scores for the mice analyzed in A–C. Data are presented as median (line in box), 25%–75% percentile range (bounds of the box), minimum and maximum (whiskers). The number of samples in individual experiments may be lower if mice had to be euthanized before the end of the experiment or technical issues appeared (for detailed information see Supporting Data Values file). Statistical test was 1-way ANOVA and Tukey’s post hoc test. ****P < 0.0001; **P < 0.01; *P < 0.05. NS, not significant; CFU, colony-forming units.
Anti Tlr2 T2 5 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tlr2+mab/TLR2%2C+Mouse%2FHuman%2C+mAb+T2%2E5/pm38358825-226-35-42
Average 94 stars, based on 1 article reviews
anti tlr2 t2 5 antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Hycult Biotech tlr2
Figure 1. Strong pneumococcal meningitis phenotypes of <t>3d/Tlr2/4–/–</t> and Myd88–/– mice are largely indistinguish- able. (A–D) Pneumococcal meningitis was elicited by intracisternal injection of 1 × 105 CFU viable Streptococcus pneumoniae. Eighteen hours postinfection (p.i.), mice of the indicated genotypes (WT, n = 18; <t>Tlr2/4–/–,</t> n = 10; 3d/ <t>Tlr2/4–/–,</t> n = 10; Myd88–/–, n = 9; negative control with PBS, n = 8) were analyzed. After clinical examination (including the collection of clinical score values), CSF was obtained to determine leukocyte counts (A). Subsequently, the mice were sacrificed, and cerebellum (B) and blood (C) samples were collected for bacterial titer determinations. (D) Clinical scores for the mice analyzed in A–C. Data are presented as median (line in box), 25%–75% percentile range (bounds of the box), minimum and maximum (whiskers). The number of samples in individual experiments may be lower if mice had to be euthanized before the end of the experiment or technical issues appeared (for detailed information see Supporting Data Values file). Statistical test was 1-way ANOVA and Tukey’s post hoc test. ****P < 0.0001; **P < 0.01; *P < 0.05. NS, not significant; CFU, colony-forming units.
Tlr2, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tlr2+mab/TLR2%2C+Mouse%2FHuman%2C+mAb+T2%2E5/pm37978545-102-25-30
Average 94 stars, based on 1 article reviews
tlr2 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc human tlr2
Figure 1. Strong pneumococcal meningitis phenotypes of <t>3d/Tlr2/4–/–</t> and Myd88–/– mice are largely indistinguish- able. (A–D) Pneumococcal meningitis was elicited by intracisternal injection of 1 × 105 CFU viable Streptococcus pneumoniae. Eighteen hours postinfection (p.i.), mice of the indicated genotypes (WT, n = 18; <t>Tlr2/4–/–,</t> n = 10; 3d/ <t>Tlr2/4–/–,</t> n = 10; Myd88–/–, n = 9; negative control with PBS, n = 8) were analyzed. After clinical examination (including the collection of clinical score values), CSF was obtained to determine leukocyte counts (A). Subsequently, the mice were sacrificed, and cerebellum (B) and blood (C) samples were collected for bacterial titer determinations. (D) Clinical scores for the mice analyzed in A–C. Data are presented as median (line in box), 25%–75% percentile range (bounds of the box), minimum and maximum (whiskers). The number of samples in individual experiments may be lower if mice had to be euthanized before the end of the experiment or technical issues appeared (for detailed information see Supporting Data Values file). Statistical test was 1-way ANOVA and Tukey’s post hoc test. ****P < 0.0001; **P < 0.01; *P < 0.05. NS, not significant; CFU, colony-forming units.
Human Tlr2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+tlr2+mab/Toll-like+Receptor+2+Rabbit+mAb/pmc09878325-66-45-47
Average 95 stars, based on 1 article reviews
human tlr2 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

Image Search Results


Pneumococcal challenge in human CSF generated higher release of LDH, IL-6 and IL-8 by Ben-Men-1 cells. Ben-Men-1 cells were challenged with increasing concentrations of SP D39 (0.25/0.5/1/2x10 7 CFU/ml) while being held in human CSF from 8 different donors (n=3-6, control: MCM) for 24h. Negative control was pure bacterial THY growth medium. Supernatants were analyzed for LDH (positive control: triton 1%), IL-6 and IL-8 (A, C) . (B) = Summary of data from (A–C) . During pneumococcal challenge (2x10 7 CFU/ml, MCM, negative controls: THY medium, PBS), cells were treated with the following inhibitors: TLR-cocktail (25µg/ml anti-TLR2 antibody + 5µM TLR4 inhibitor + 20µg/ml chloroquine), 0.1-10 µM BAY 11-7082, 0.01-1µM 666-15, 0.01-1µM JQ1 or DMSO control. (D) Supernatants were analyzed for LDH and IL-6. Data are given as individual values as well as means ± SD.

Journal: Frontiers in Immunology

Article Title: Macrophage IL-1β turns meningeal fibroblasts into inflammatory amplifiers in pneumococcal infection

doi: 10.3389/fimmu.2026.1808185

Figure Lengend Snippet: Pneumococcal challenge in human CSF generated higher release of LDH, IL-6 and IL-8 by Ben-Men-1 cells. Ben-Men-1 cells were challenged with increasing concentrations of SP D39 (0.25/0.5/1/2x10 7 CFU/ml) while being held in human CSF from 8 different donors (n=3-6, control: MCM) for 24h. Negative control was pure bacterial THY growth medium. Supernatants were analyzed for LDH (positive control: triton 1%), IL-6 and IL-8 (A, C) . (B) = Summary of data from (A–C) . During pneumococcal challenge (2x10 7 CFU/ml, MCM, negative controls: THY medium, PBS), cells were treated with the following inhibitors: TLR-cocktail (25µg/ml anti-TLR2 antibody + 5µM TLR4 inhibitor + 20µg/ml chloroquine), 0.1-10 µM BAY 11-7082, 0.01-1µM 666-15, 0.01-1µM JQ1 or DMSO control. (D) Supernatants were analyzed for LDH and IL-6. Data are given as individual values as well as means ± SD.

Article Snippet: In addition, TLR signaling was assessed using an anti-TLR2 mAB T2.5 (25μg/ml, Hycult), TLR4 inhibitor TAK-242 (5μM, Calbiochem, USA) and chloroquine (20μg/ml, Sigma-Aldrich, USA) to inhibit endosomal TLRs ( ).

Techniques: Generated, Control, Negative Control, Positive Control

Primary human meningeal cells display partially PLY-dependent cell death and cytokine release upon pneumococcal challenge. HMC were challenged with P/S-lysed S. pneumoniae serotype 2 (D39), D39Δ ply , serotypes 6B and 7F (0.25/1/4x10 7 CFU/ml, negative control: THY bacterial medium without bacteria) for 24h. Supernatants were analyzed for LDH (C, D) and IL-6 release (B, E) After exposure to THY, D39 or D39Δ ply (4x10 7 CFU/ml), supernatants were pooled and analyzed with antibody array. (A) HMC were treated during pneumococcal challenge (4x10 7 CFU/ml) with the following inhibitors: TLR-cocktail (anti-TLR2 antibody T2.5 (25µg/ml) + TLR4 inhibitor TAK-242 (5µM) + endosomal TLR inhibitor chloroquine (20µg/ml)), NF-κB inhibitors parthenolide (0.5µM) and BAY 11-7082 (1-10 µM), AP-1 inhibitor SR11302 (1µM), BRD4 inhibitors I-BET (10µM) and JQ1 (1µM), CREB inhibitors KG-501 (10µM) and 666-15 (1µM), or DMSO control. (D, E) Data are given as individual values as well as means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Statistical analysis was calculated with ANOVA with Tukey’s multiple comparison test.

Journal: Frontiers in Immunology

Article Title: Macrophage IL-1β turns meningeal fibroblasts into inflammatory amplifiers in pneumococcal infection

doi: 10.3389/fimmu.2026.1808185

Figure Lengend Snippet: Primary human meningeal cells display partially PLY-dependent cell death and cytokine release upon pneumococcal challenge. HMC were challenged with P/S-lysed S. pneumoniae serotype 2 (D39), D39Δ ply , serotypes 6B and 7F (0.25/1/4x10 7 CFU/ml, negative control: THY bacterial medium without bacteria) for 24h. Supernatants were analyzed for LDH (C, D) and IL-6 release (B, E) After exposure to THY, D39 or D39Δ ply (4x10 7 CFU/ml), supernatants were pooled and analyzed with antibody array. (A) HMC were treated during pneumococcal challenge (4x10 7 CFU/ml) with the following inhibitors: TLR-cocktail (anti-TLR2 antibody T2.5 (25µg/ml) + TLR4 inhibitor TAK-242 (5µM) + endosomal TLR inhibitor chloroquine (20µg/ml)), NF-κB inhibitors parthenolide (0.5µM) and BAY 11-7082 (1-10 µM), AP-1 inhibitor SR11302 (1µM), BRD4 inhibitors I-BET (10µM) and JQ1 (1µM), CREB inhibitors KG-501 (10µM) and 666-15 (1µM), or DMSO control. (D, E) Data are given as individual values as well as means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Statistical analysis was calculated with ANOVA with Tukey’s multiple comparison test.

Article Snippet: In addition, TLR signaling was assessed using an anti-TLR2 mAB T2.5 (25μg/ml, Hycult), TLR4 inhibitor TAK-242 (5μM, Calbiochem, USA) and chloroquine (20μg/ml, Sigma-Aldrich, USA) to inhibit endosomal TLRs ( ).

Techniques: Negative Control, Bacteria, Ab Array, Control, Comparison

TLR2 is required for MutuDC sensing of, but not internalization of MRSA (A) Relative pHrodo labeled MRSA internalization by MutuDC over 4 h following stimulation with DapS A8819 (light blue symbols) or DapR A8817 (dark blue symbols), or media alone (white squares). Prior to stimulation, MutuDC were pre-treated for 1 h with TLR2 blocking antibody (clone T2.5; triangles with dashed lines) or media alone (circles with filled lines). Relative MRSA internalization by each DC subset is expressed as the gMFI of pHrodo. Results show the mean and (SD) of duplicates from one experiment, representative of two independent experiments. (B) Cytokine secretion (pg/mL) by MutuDC stimulated with TLR2 ligand peptidoglycan of S. aureus (PGN-SA) (10 μg/mL) or (C) DapS (A8819; light blue) or DapR (A8817; dark blue) MRSA (MOI of 10) for 18 h. MutuDC were first pre-treated with either TLR2 blocking antibody (dot-filled bars) or media alone (filled bars) as in A, or an isotype control (clone 163D3, empty bars) at 1 μg/mL. Results pooled from four (B) or three (C) independent experiments and expressed as the mean ± SEM, with each symbol (circle, square, and directional triangles) representing paired experimental replicates ( n = 3). Statistical significance determined using paired t test and reported as indicated by an ∗ when p ≤ 0.05. (D) Expression of surface activation markers by MutuDC stimulated with DapS A8819 MRSA. DC were pre-treated with TLR2 blocking antibody (black trace), isotype control (dashed red trace), and media alone (light blue shaded). Unstained control sample is shown for each marker (black dashed trace). Data shown from one experiment, representative of three independent experiments.

Journal: iScience

Article Title: cGAS/STING sensing in dendritic cells discriminates between daptomycin sensitive and resistant Staphylococcus aureus clinical isolates

doi: 10.1016/j.isci.2026.115854

Figure Lengend Snippet: TLR2 is required for MutuDC sensing of, but not internalization of MRSA (A) Relative pHrodo labeled MRSA internalization by MutuDC over 4 h following stimulation with DapS A8819 (light blue symbols) or DapR A8817 (dark blue symbols), or media alone (white squares). Prior to stimulation, MutuDC were pre-treated for 1 h with TLR2 blocking antibody (clone T2.5; triangles with dashed lines) or media alone (circles with filled lines). Relative MRSA internalization by each DC subset is expressed as the gMFI of pHrodo. Results show the mean and (SD) of duplicates from one experiment, representative of two independent experiments. (B) Cytokine secretion (pg/mL) by MutuDC stimulated with TLR2 ligand peptidoglycan of S. aureus (PGN-SA) (10 μg/mL) or (C) DapS (A8819; light blue) or DapR (A8817; dark blue) MRSA (MOI of 10) for 18 h. MutuDC were first pre-treated with either TLR2 blocking antibody (dot-filled bars) or media alone (filled bars) as in A, or an isotype control (clone 163D3, empty bars) at 1 μg/mL. Results pooled from four (B) or three (C) independent experiments and expressed as the mean ± SEM, with each symbol (circle, square, and directional triangles) representing paired experimental replicates ( n = 3). Statistical significance determined using paired t test and reported as indicated by an ∗ when p ≤ 0.05. (D) Expression of surface activation markers by MutuDC stimulated with DapS A8819 MRSA. DC were pre-treated with TLR2 blocking antibody (black trace), isotype control (dashed red trace), and media alone (light blue shaded). Unstained control sample is shown for each marker (black dashed trace). Data shown from one experiment, representative of three independent experiments.

Article Snippet: mAB mTLR2- anti-mouse/human TLR2 , InvivoGen , Cat# mab-mtlr2; RRID: AB_763722.

Techniques: Labeling, Blocking Assay, Control, Expressing, Activation Assay, Marker, FACS

Journal: iScience

Article Title: cGAS/STING sensing in dendritic cells discriminates between daptomycin sensitive and resistant Staphylococcus aureus clinical isolates

doi: 10.1016/j.isci.2026.115854

Figure Lengend Snippet:

Article Snippet: mAB mTLR2- anti-mouse/human TLR2 , InvivoGen , Cat# mab-mtlr2; RRID: AB_763722.

Techniques: Purification, Cell-Signaling, Enzyme-linked Immunosorbent Assay, Western Blot, Virus, Recombinant, Transfection, Derivative Assay, Expressing, Clone Assay, Plasmid Preparation, Software

Fig. 1. TLR2 knockout reduces tau pathology and alleviates cognitive functions in rTg4510 mice. (A) Differential RNA expression of TLRs in AD brains compared to cognitively normal controls. Log2 fold changes are indicated. ACC, anterior cingulate cortex; CBE, cerebellum; DLPFC, dorsolateral prefrontal cortex; FP, frontal pole; IFG, inferior frontal gyrus; PCC, posterior cingulate cortex; PHG, parahippocampal gyrus; STG, superior temporal gyrus; TCX, temporal cortex. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. (B-D) Tlr2 KO ameliorates cognitive impairment in rTg4510 mice. The 6-month-old mice (tTA/WT, tTA/Tlr2 KO, rTg4510/ WT, rTg4510/Tlr2 KO) were analyzed with the Y-maze test [B, two-way ANOVA with Tukey test, n (male, female) = 10 (7, 3); 10 (2, 8); 8 (6, 2); 11 (4, 7)], novel object recognition test [C, two-way ANOVA with Tukey test, n (male, female) = 8 (5, 3); 7 (2, 5); 6 (4, 2); 7 (2, 5)], and passive avoidance test [D, paired t-test, n (male, female) = 10 (7, 3); 10 (2, 8); 9 (6, 3); 11 (4, 7)]. (E-G) Tlr2 KO reduces tau pathology and microglial activation in rTg4510 mice. Immunohistochemistry of AT8 and Iba1 in the frontal cortex, dentate gyrus, and entorhinal cortex (E). Scale bar, 20 μm. Quantification of AT8 signal intensities (F) and the number of Iba1- positive cells (G). Two-way ANOVA with Tukey test, n = 7, 6, 3, 5. Data are represented as mean ± SEM. N.S., not significant.

Journal: Brain, behavior, and immunity

Article Title: TLR2 immunotherapy suppresses neuroinflammation, tau spread, and memory loss in rTg4510 mice.

doi: 10.1016/j.bbi.2024.08.002

Figure Lengend Snippet: Fig. 1. TLR2 knockout reduces tau pathology and alleviates cognitive functions in rTg4510 mice. (A) Differential RNA expression of TLRs in AD brains compared to cognitively normal controls. Log2 fold changes are indicated. ACC, anterior cingulate cortex; CBE, cerebellum; DLPFC, dorsolateral prefrontal cortex; FP, frontal pole; IFG, inferior frontal gyrus; PCC, posterior cingulate cortex; PHG, parahippocampal gyrus; STG, superior temporal gyrus; TCX, temporal cortex. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. (B-D) Tlr2 KO ameliorates cognitive impairment in rTg4510 mice. The 6-month-old mice (tTA/WT, tTA/Tlr2 KO, rTg4510/ WT, rTg4510/Tlr2 KO) were analyzed with the Y-maze test [B, two-way ANOVA with Tukey test, n (male, female) = 10 (7, 3); 10 (2, 8); 8 (6, 2); 11 (4, 7)], novel object recognition test [C, two-way ANOVA with Tukey test, n (male, female) = 8 (5, 3); 7 (2, 5); 6 (4, 2); 7 (2, 5)], and passive avoidance test [D, paired t-test, n (male, female) = 10 (7, 3); 10 (2, 8); 9 (6, 3); 11 (4, 7)]. (E-G) Tlr2 KO reduces tau pathology and microglial activation in rTg4510 mice. Immunohistochemistry of AT8 and Iba1 in the frontal cortex, dentate gyrus, and entorhinal cortex (E). Scale bar, 20 μm. Quantification of AT8 signal intensities (F) and the number of Iba1- positive cells (G). Two-way ANOVA with Tukey test, n = 7, 6, 3, 5. Data are represented as mean ± SEM. N.S., not significant.

Article Snippet: The primary antibodies used in the study: Tomaralimab (Amyloid Solution Inc., 1:250), anti-human TLR2 (Cell Signaling Technology #12276, 1:1000), anti-mouse TLR2 (Cell Signaling Technology #13744, 1:1000), anti-human tau HT7 (Invitrogen #MN1000, 1:1000), antiTau4R (Cell Signaling Technology #30328, 1:1000), anti-phospho-tau AT8 (Invitrogen #MN1020, 1:500), anti-Iba1 (GeneTex #GTX635400, 1:500), anti-Iba1 (Wako #019-19741, 1:1000), anti-MAP2 (Cell Signaling Technology #4542, 1:500), anti-NeuN (Millipore #MAB377, 1:1000), anti-GFAP (Cell Signaling Technology #80788, 1:1000), antiMyD88 (Cell Signaling Technology #50010, 1:1000), anti-NLRP3 (Cell Signaling Technology #15101, 1:1000), anti-β-actin (Santa Cruz Biotechnology #sc-47778, 1:1000), anti-GFP (Santa Cruz Biotechnology #sc-9996, 1:3000), anti-His-Tag (Cell Signaling Technology #2365, 1:1000).

Techniques: Knock-Out, RNA Expression, Activation Assay, Immunohistochemistry

Fig. 2. Microglial TLR2 binds to oligomeric tau. (A) Monomeric tau (mTau) and oligomeric tau (oTau) proteins prepared in vitro were subjected to native PAGE and stained with Coomassie Brilliant Blue or immunoblotted with anti-human tau (HT7) antibody. (B-C) TLR2 preferentially binds to oTau. Extracts of HEK293T cells transfected with TLR2-GFP were incubated without (None) or with either mTau or oTau (250 nM, 12 h) and subjected to immunoprecipitation (IP) (B). The signals of TLR2 on the blots were measured by ImageJ (C). One-way ANOVA with Holm-ˇSíd´ak test, n = 3. (D-E) Mapping of TLR2 domains involved in tau binding. A schematic diagram of TLR2 domains and mutants (ΔLBD, ΔDimer, D327W/F349L, P681H) (D). HEK293T cells were transfected with either WT or mutant TLR2-GFP. Cell lysates were incubated with 250 nM oTau and subjected to immunoprecipitation (IP) (E). (F-G) TLR2 activation increases binding of oligomeric tau. BV2 cells were left untreated (Nontreat) or incubated with Pam3CSK4 (10 μg/ml) overnight and then incubated with DyLight 488-labeled mTau or oTau (200 nM, 4 h). Cells were washed and immunostained with anti-TLR2 antibody (F). Scale bar, 10 μm. TLR2-bound DyLight 488 signals were measured by ImageJ (G). Two-way ANOVA with Tukey test, n = 3, 50 cells per group. Data are represented as mean ± SEM.

Journal: Brain, behavior, and immunity

Article Title: TLR2 immunotherapy suppresses neuroinflammation, tau spread, and memory loss in rTg4510 mice.

doi: 10.1016/j.bbi.2024.08.002

Figure Lengend Snippet: Fig. 2. Microglial TLR2 binds to oligomeric tau. (A) Monomeric tau (mTau) and oligomeric tau (oTau) proteins prepared in vitro were subjected to native PAGE and stained with Coomassie Brilliant Blue or immunoblotted with anti-human tau (HT7) antibody. (B-C) TLR2 preferentially binds to oTau. Extracts of HEK293T cells transfected with TLR2-GFP were incubated without (None) or with either mTau or oTau (250 nM, 12 h) and subjected to immunoprecipitation (IP) (B). The signals of TLR2 on the blots were measured by ImageJ (C). One-way ANOVA with Holm-ˇSíd´ak test, n = 3. (D-E) Mapping of TLR2 domains involved in tau binding. A schematic diagram of TLR2 domains and mutants (ΔLBD, ΔDimer, D327W/F349L, P681H) (D). HEK293T cells were transfected with either WT or mutant TLR2-GFP. Cell lysates were incubated with 250 nM oTau and subjected to immunoprecipitation (IP) (E). (F-G) TLR2 activation increases binding of oligomeric tau. BV2 cells were left untreated (Nontreat) or incubated with Pam3CSK4 (10 μg/ml) overnight and then incubated with DyLight 488-labeled mTau or oTau (200 nM, 4 h). Cells were washed and immunostained with anti-TLR2 antibody (F). Scale bar, 10 μm. TLR2-bound DyLight 488 signals were measured by ImageJ (G). Two-way ANOVA with Tukey test, n = 3, 50 cells per group. Data are represented as mean ± SEM.

Article Snippet: The primary antibodies used in the study: Tomaralimab (Amyloid Solution Inc., 1:250), anti-human TLR2 (Cell Signaling Technology #12276, 1:1000), anti-mouse TLR2 (Cell Signaling Technology #13744, 1:1000), anti-human tau HT7 (Invitrogen #MN1000, 1:1000), antiTau4R (Cell Signaling Technology #30328, 1:1000), anti-phospho-tau AT8 (Invitrogen #MN1020, 1:500), anti-Iba1 (GeneTex #GTX635400, 1:500), anti-Iba1 (Wako #019-19741, 1:1000), anti-MAP2 (Cell Signaling Technology #4542, 1:500), anti-NeuN (Millipore #MAB377, 1:1000), anti-GFAP (Cell Signaling Technology #80788, 1:1000), antiMyD88 (Cell Signaling Technology #50010, 1:1000), anti-NLRP3 (Cell Signaling Technology #15101, 1:1000), anti-β-actin (Santa Cruz Biotechnology #sc-47778, 1:1000), anti-GFP (Santa Cruz Biotechnology #sc-9996, 1:3000), anti-His-Tag (Cell Signaling Technology #2365, 1:1000).

Techniques: In Vitro, Clear Native PAGE, Staining, Transfection, Incubation, Immunoprecipitation, Binding Assay, Mutagenesis, Activation Assay, Labeling

Fig. 4. Tau-induced TLR2 activation in microglia promotes neuronal tau uptake. (A-B) Microglial TLR2 increases neuronal tau uptake in neuron-microglia co- culture system. WT and Tlr2 KO mouse primary cortical neurons (DIV 7) and microglia (DIV 14) were co-cultured and treated with DyLight 488-oligomeric tau (200 nM, 24 h) (A). Scale bar, 10 μm. DyLight 488 intensities in MAP2-positive neurons (arrowheads) were measured (B). Two-way ANOVA with Tukey test, n = 3, 28–58 cells per group. (C-D) Tlr2 deficiency reduces tau-induced microglial activation in the mouse hippocampus. Tau oligomers (6 μg) were intracranially injected into the hippocampus of 4-month-old mice. After 7 days, brain sections were immunostained with anti-human tau (HT7) and anti-Iba1 antibodies (C). Scale bar, 50 μm. Manders’ colocalization coefficient (fraction of HT7 overlapping Iba1) was measured (D). Unpaired t-test, two-tailed, n = 3 per group. (E-F) Tlr2 deficiency reduces neuronal tau uptake in the mouse hippocampus. Tau oligomers (6 μg) were intracranially injected into the hippocampus of 3-month-old mice. After 48 h, brain sections were immunostained with anti-human tau (HT7) and anti-MAP2 antibodies (E). Arrowheads indicate internalized tau oligomers. Scale bar, 10 μm. Per- centages of HT7-positive neurons in the injection area were estimated (F). Unpaired t-test, two-tailed, n = 3 per group. Data are represented as mean ± SEM.

Journal: Brain, behavior, and immunity

Article Title: TLR2 immunotherapy suppresses neuroinflammation, tau spread, and memory loss in rTg4510 mice.

doi: 10.1016/j.bbi.2024.08.002

Figure Lengend Snippet: Fig. 4. Tau-induced TLR2 activation in microglia promotes neuronal tau uptake. (A-B) Microglial TLR2 increases neuronal tau uptake in neuron-microglia co- culture system. WT and Tlr2 KO mouse primary cortical neurons (DIV 7) and microglia (DIV 14) were co-cultured and treated with DyLight 488-oligomeric tau (200 nM, 24 h) (A). Scale bar, 10 μm. DyLight 488 intensities in MAP2-positive neurons (arrowheads) were measured (B). Two-way ANOVA with Tukey test, n = 3, 28–58 cells per group. (C-D) Tlr2 deficiency reduces tau-induced microglial activation in the mouse hippocampus. Tau oligomers (6 μg) were intracranially injected into the hippocampus of 4-month-old mice. After 7 days, brain sections were immunostained with anti-human tau (HT7) and anti-Iba1 antibodies (C). Scale bar, 50 μm. Manders’ colocalization coefficient (fraction of HT7 overlapping Iba1) was measured (D). Unpaired t-test, two-tailed, n = 3 per group. (E-F) Tlr2 deficiency reduces neuronal tau uptake in the mouse hippocampus. Tau oligomers (6 μg) were intracranially injected into the hippocampus of 3-month-old mice. After 48 h, brain sections were immunostained with anti-human tau (HT7) and anti-MAP2 antibodies (E). Arrowheads indicate internalized tau oligomers. Scale bar, 10 μm. Per- centages of HT7-positive neurons in the injection area were estimated (F). Unpaired t-test, two-tailed, n = 3 per group. Data are represented as mean ± SEM.

Article Snippet: The primary antibodies used in the study: Tomaralimab (Amyloid Solution Inc., 1:250), anti-human TLR2 (Cell Signaling Technology #12276, 1:1000), anti-mouse TLR2 (Cell Signaling Technology #13744, 1:1000), anti-human tau HT7 (Invitrogen #MN1000, 1:1000), antiTau4R (Cell Signaling Technology #30328, 1:1000), anti-phospho-tau AT8 (Invitrogen #MN1020, 1:500), anti-Iba1 (GeneTex #GTX635400, 1:500), anti-Iba1 (Wako #019-19741, 1:1000), anti-MAP2 (Cell Signaling Technology #4542, 1:500), anti-NeuN (Millipore #MAB377, 1:1000), anti-GFAP (Cell Signaling Technology #80788, 1:1000), antiMyD88 (Cell Signaling Technology #50010, 1:1000), anti-NLRP3 (Cell Signaling Technology #15101, 1:1000), anti-β-actin (Santa Cruz Biotechnology #sc-47778, 1:1000), anti-GFP (Santa Cruz Biotechnology #sc-9996, 1:3000), anti-His-Tag (Cell Signaling Technology #2365, 1:1000).

Techniques: Activation Assay, Co-Culture Assay, Cell Culture, Injection, Two Tailed Test

Figure 1. Strong pneumococcal meningitis phenotypes of 3d/Tlr2/4–/– and Myd88–/– mice are largely indistinguish- able. (A–D) Pneumococcal meningitis was elicited by intracisternal injection of 1 × 105 CFU viable Streptococcus pneumoniae. Eighteen hours postinfection (p.i.), mice of the indicated genotypes (WT, n = 18; Tlr2/4–/–, n = 10; 3d/ Tlr2/4–/–, n = 10; Myd88–/–, n = 9; negative control with PBS, n = 8) were analyzed. After clinical examination (including the collection of clinical score values), CSF was obtained to determine leukocyte counts (A). Subsequently, the mice were sacrificed, and cerebellum (B) and blood (C) samples were collected for bacterial titer determinations. (D) Clinical scores for the mice analyzed in A–C. Data are presented as median (line in box), 25%–75% percentile range (bounds of the box), minimum and maximum (whiskers). The number of samples in individual experiments may be lower if mice had to be euthanized before the end of the experiment or technical issues appeared (for detailed information see Supporting Data Values file). Statistical test was 1-way ANOVA and Tukey’s post hoc test. ****P < 0.0001; **P < 0.01; *P < 0.05. NS, not significant; CFU, colony-forming units.

Journal: JCI insight

Article Title: Combining antibiotic with anti-TLR2/TLR13 therapy prevents brain pathology in pneumococcal meningitis.

doi: 10.1172/jci.insight.165737

Figure Lengend Snippet: Figure 1. Strong pneumococcal meningitis phenotypes of 3d/Tlr2/4–/– and Myd88–/– mice are largely indistinguish- able. (A–D) Pneumococcal meningitis was elicited by intracisternal injection of 1 × 105 CFU viable Streptococcus pneumoniae. Eighteen hours postinfection (p.i.), mice of the indicated genotypes (WT, n = 18; Tlr2/4–/–, n = 10; 3d/ Tlr2/4–/–, n = 10; Myd88–/–, n = 9; negative control with PBS, n = 8) were analyzed. After clinical examination (including the collection of clinical score values), CSF was obtained to determine leukocyte counts (A). Subsequently, the mice were sacrificed, and cerebellum (B) and blood (C) samples were collected for bacterial titer determinations. (D) Clinical scores for the mice analyzed in A–C. Data are presented as median (line in box), 25%–75% percentile range (bounds of the box), minimum and maximum (whiskers). The number of samples in individual experiments may be lower if mice had to be euthanized before the end of the experiment or technical issues appeared (for detailed information see Supporting Data Values file). Statistical test was 1-way ANOVA and Tukey’s post hoc test. ****P < 0.0001; **P < 0.01; *P < 0.05. NS, not significant; CFU, colony-forming units.

Article Snippet: In order to assess the efficacy of TLR antagonism in the adjunctive treatment of pneumococcal meningitis, WT mice (n = 10) were i.p. treated with a cocktail of ceftriaxone (100 mg/kg body weight), a neutralizing anti-TLR2 T2.5 antibody (30 mg/kg body weight; Hycult Biotech, HM1054) (25, 26), and CQ (50 mg/kg body weight; Sigma-Aldrich) (27, 28) 18 hours p.i. and examined 24 hours thereafter (42 hours p.i.).

Techniques: Injection, Negative Control

Figure 2. TLR13 mediates pathogen recognition in addition to TLR2 in murine pneumococcal meningitis. (A–F) Pneu- mococcal meningitis was modeled as specified for Figure 1 in mice of the 7 genotypes indicated (WT, n = 18; Tlr3/7/9–/–, n = 9; 3d, n = 9; Tlr2/3/4/7/9–/–, n = 10; Tlr2/4/13–/–, n = 10; Tlr2/13–/–, n = 10; 3d/Tlr2/4–/–, n = 10). CSF leukocyte counts (A), brain IL-1β (B) and TNF levels (C), brain bacterial loads (D), ICP (E), and clinical score values (F) were measured. Data are presented as median (line within box), 25%–75% percentile range (bounds of the box), and minimum and maxi- mum (whiskers). The data from the WT and 3d/Tlr2/4–/– groups (boxes shown in gray) correspond to those in Figure 1. The number of samples in individual experiments may be lower if mice had to be euthanized before the end of the experiment or technical issues appeared (for detailed information see Supporting Data Values file). Statistical test was 1-way ANOVA and subsequent Tukey’s post hoc test. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05, as compared with infected WT mice–derived samples. NS, not significant.

Journal: JCI insight

Article Title: Combining antibiotic with anti-TLR2/TLR13 therapy prevents brain pathology in pneumococcal meningitis.

doi: 10.1172/jci.insight.165737

Figure Lengend Snippet: Figure 2. TLR13 mediates pathogen recognition in addition to TLR2 in murine pneumococcal meningitis. (A–F) Pneu- mococcal meningitis was modeled as specified for Figure 1 in mice of the 7 genotypes indicated (WT, n = 18; Tlr3/7/9–/–, n = 9; 3d, n = 9; Tlr2/3/4/7/9–/–, n = 10; Tlr2/4/13–/–, n = 10; Tlr2/13–/–, n = 10; 3d/Tlr2/4–/–, n = 10). CSF leukocyte counts (A), brain IL-1β (B) and TNF levels (C), brain bacterial loads (D), ICP (E), and clinical score values (F) were measured. Data are presented as median (line within box), 25%–75% percentile range (bounds of the box), and minimum and maxi- mum (whiskers). The data from the WT and 3d/Tlr2/4–/– groups (boxes shown in gray) correspond to those in Figure 1. The number of samples in individual experiments may be lower if mice had to be euthanized before the end of the experiment or technical issues appeared (for detailed information see Supporting Data Values file). Statistical test was 1-way ANOVA and subsequent Tukey’s post hoc test. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05, as compared with infected WT mice–derived samples. NS, not significant.

Article Snippet: In order to assess the efficacy of TLR antagonism in the adjunctive treatment of pneumococcal meningitis, WT mice (n = 10) were i.p. treated with a cocktail of ceftriaxone (100 mg/kg body weight), a neutralizing anti-TLR2 T2.5 antibody (30 mg/kg body weight; Hycult Biotech, HM1054) (25, 26), and CQ (50 mg/kg body weight; Sigma-Aldrich) (27, 28) 18 hours p.i. and examined 24 hours thereafter (42 hours p.i.).

Techniques: Infection, Derivative Assay

Figure 3. The adjunctive use of neutralizing anti-TLR2 monoclonal antibody and chloroquine in antibiotic therapy provides significantly greater benefits to mice with pneumococcal meningitis as compared with administration of dexamethasone. (A–J) Pneumococcal meningitis was elicited by intracisternal injection of viable Streptococcus pneumoniae (with PBS as negative control, n = 4). Eighteen hours postinfection (p.i.), animals were treated with ceftriaxone (n = 10) and a cocktail of neutralizing anti-TLR2 mAb (T2.5) and chloroquine (CQ) (n = 10), with the additional (n = 10) or alternative (n = 12) administration of dexamethasone (DEXA) or placebo (n = 14). At 42 hours p.i., CSF leukocyte counts (A), bacterial load (B), intracranial pressure (ICP) (C), the number of cerebral hemorrhages (D), as well as plasma concentrations of neurofilament light chain (NEFL) (E) and S100B (F) — 2 biomarkers for brain injury — were evaluated. Mice also underwent clinical examination, including the assessment of weight loss (G), motor activity (H), and clinical scores (I). (J) Brain sections from representative mice of the investigated groups. Data are presented as median (line in box), 25%–75% percentile range (bounds of the box), and minimum and maximum (whiskers). The number of samples in individual experiments may be lower if mice had to be euthanized before the end of the experiment or technical issues appeared (for detailed information see Supporting Data Values file). Statistical test was 1-way ANOVA and subsequent Tukey’s post hoc test. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05. NS, not significant; CEF, ceftriaxone.

Journal: JCI insight

Article Title: Combining antibiotic with anti-TLR2/TLR13 therapy prevents brain pathology in pneumococcal meningitis.

doi: 10.1172/jci.insight.165737

Figure Lengend Snippet: Figure 3. The adjunctive use of neutralizing anti-TLR2 monoclonal antibody and chloroquine in antibiotic therapy provides significantly greater benefits to mice with pneumococcal meningitis as compared with administration of dexamethasone. (A–J) Pneumococcal meningitis was elicited by intracisternal injection of viable Streptococcus pneumoniae (with PBS as negative control, n = 4). Eighteen hours postinfection (p.i.), animals were treated with ceftriaxone (n = 10) and a cocktail of neutralizing anti-TLR2 mAb (T2.5) and chloroquine (CQ) (n = 10), with the additional (n = 10) or alternative (n = 12) administration of dexamethasone (DEXA) or placebo (n = 14). At 42 hours p.i., CSF leukocyte counts (A), bacterial load (B), intracranial pressure (ICP) (C), the number of cerebral hemorrhages (D), as well as plasma concentrations of neurofilament light chain (NEFL) (E) and S100B (F) — 2 biomarkers for brain injury — were evaluated. Mice also underwent clinical examination, including the assessment of weight loss (G), motor activity (H), and clinical scores (I). (J) Brain sections from representative mice of the investigated groups. Data are presented as median (line in box), 25%–75% percentile range (bounds of the box), and minimum and maximum (whiskers). The number of samples in individual experiments may be lower if mice had to be euthanized before the end of the experiment or technical issues appeared (for detailed information see Supporting Data Values file). Statistical test was 1-way ANOVA and subsequent Tukey’s post hoc test. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05. NS, not significant; CEF, ceftriaxone.

Article Snippet: In order to assess the efficacy of TLR antagonism in the adjunctive treatment of pneumococcal meningitis, WT mice (n = 10) were i.p. treated with a cocktail of ceftriaxone (100 mg/kg body weight), a neutralizing anti-TLR2 T2.5 antibody (30 mg/kg body weight; Hycult Biotech, HM1054) (25, 26), and CQ (50 mg/kg body weight; Sigma-Aldrich) (27, 28) 18 hours p.i. and examined 24 hours thereafter (42 hours p.i.).

Techniques: Injection, Negative Control, Clinical Proteomics, Activity Assay

Figure 4. Dual neutralizing TLR2 mAb and CQ application in vitro abrogates Streptococcus pneumoniae–induced cytokine release by murine and human immune cells. (A and B) Murine BMDMs (blue boxes) and (C–F) human PBMCs (green boxes) were cultured and challenged with 1 × 106 CFU/mL viable S. pneumoniae (SP, except for controls, which received THY solution only). Four hours postinfection (p.i.), cells were treated with ceftriaxone. Two hours earlier (2 h), simultaneously (4 h), or 2 hours later (6 h p.i.), anti-TLR2 mAb (T2.5) and chloroquine (CQ) were added to cell cultures. In human PBMC cultures, the TLR8 inhibitor Cu-Cpt9a and dexamethasone (DEXA) were applied additionally where indicated. Cell culture supernatants were sampled 24 hours p.i., aliquoted, and stored until ELISA analysis. Supernatants were analyzed for IL-6 (A–D), IL-1β (E), and TNF (F). The experiments with BMDMs were conducted at least 2 times in triplicate, while those involving human PBMCs were performed at least 2 times in quadruplicate (for detailed information see Supporting Data Values file). The data for the placebo and T2.5 plus CQ (4 h) groups in A and B (as indicated by blue boxes with gray diagonal stripes in B) largely overlap. Data are depicted as median (line in box), 25%–75% percentile range (bounds of the box), and minimum and maximum (whiskers). Statis- tical test was 1-way ANOVA and subsequent Tukey’s post hoc test. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05. NS, not significant.

Journal: JCI insight

Article Title: Combining antibiotic with anti-TLR2/TLR13 therapy prevents brain pathology in pneumococcal meningitis.

doi: 10.1172/jci.insight.165737

Figure Lengend Snippet: Figure 4. Dual neutralizing TLR2 mAb and CQ application in vitro abrogates Streptococcus pneumoniae–induced cytokine release by murine and human immune cells. (A and B) Murine BMDMs (blue boxes) and (C–F) human PBMCs (green boxes) were cultured and challenged with 1 × 106 CFU/mL viable S. pneumoniae (SP, except for controls, which received THY solution only). Four hours postinfection (p.i.), cells were treated with ceftriaxone. Two hours earlier (2 h), simultaneously (4 h), or 2 hours later (6 h p.i.), anti-TLR2 mAb (T2.5) and chloroquine (CQ) were added to cell cultures. In human PBMC cultures, the TLR8 inhibitor Cu-Cpt9a and dexamethasone (DEXA) were applied additionally where indicated. Cell culture supernatants were sampled 24 hours p.i., aliquoted, and stored until ELISA analysis. Supernatants were analyzed for IL-6 (A–D), IL-1β (E), and TNF (F). The experiments with BMDMs were conducted at least 2 times in triplicate, while those involving human PBMCs were performed at least 2 times in quadruplicate (for detailed information see Supporting Data Values file). The data for the placebo and T2.5 plus CQ (4 h) groups in A and B (as indicated by blue boxes with gray diagonal stripes in B) largely overlap. Data are depicted as median (line in box), 25%–75% percentile range (bounds of the box), and minimum and maximum (whiskers). Statis- tical test was 1-way ANOVA and subsequent Tukey’s post hoc test. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05. NS, not significant.

Article Snippet: In order to assess the efficacy of TLR antagonism in the adjunctive treatment of pneumococcal meningitis, WT mice (n = 10) were i.p. treated with a cocktail of ceftriaxone (100 mg/kg body weight), a neutralizing anti-TLR2 T2.5 antibody (30 mg/kg body weight; Hycult Biotech, HM1054) (25, 26), and CQ (50 mg/kg body weight; Sigma-Aldrich) (27, 28) 18 hours p.i. and examined 24 hours thereafter (42 hours p.i.).

Techniques: In Vitro, Cell Culture, Enzyme-linked Immunosorbent Assay

Figure 5. Dual TLR inhibitor cocktail application inhibits in vitro antibiotic–treated Streptococcus pneumoniae infection–induced IL-6 release by PBMCs donated by 10 human healthy volunteers. (A–J) Cultures of peripheral blood mononuclear cells (PBMCs) from 10 healthy human individuals were challenged with increasing doses of viable S. pneumoniae (triangles, sequentially 1 × 103, 1 × 104, 1 × 105, 1 × 106, and 1 × 107 CFU/mL; controls received a sheer sterile THY solution). At the 4-hour postinfection (p.i.) time point, ceftriaxone was applied to all cultures, while anti-TLR2 mAb (T2.5) and/or chloroquine (CQ) were specifically added where indicated (rectangles, 1 × 106 CFU/ mL). Supernatants were harvested 24 hours p.i. and analyzed by ELISA. Blue, male donors (A–E); red, female donors (F–J); red and blue data points indicate challenges with 1 × 106 CFU/mL S. pneumoniae. The results are from 2 independent experiments with duplicates, presented as individ- ual dots with mean ± SD.

Journal: JCI insight

Article Title: Combining antibiotic with anti-TLR2/TLR13 therapy prevents brain pathology in pneumococcal meningitis.

doi: 10.1172/jci.insight.165737

Figure Lengend Snippet: Figure 5. Dual TLR inhibitor cocktail application inhibits in vitro antibiotic–treated Streptococcus pneumoniae infection–induced IL-6 release by PBMCs donated by 10 human healthy volunteers. (A–J) Cultures of peripheral blood mononuclear cells (PBMCs) from 10 healthy human individuals were challenged with increasing doses of viable S. pneumoniae (triangles, sequentially 1 × 103, 1 × 104, 1 × 105, 1 × 106, and 1 × 107 CFU/mL; controls received a sheer sterile THY solution). At the 4-hour postinfection (p.i.) time point, ceftriaxone was applied to all cultures, while anti-TLR2 mAb (T2.5) and/or chloroquine (CQ) were specifically added where indicated (rectangles, 1 × 106 CFU/ mL). Supernatants were harvested 24 hours p.i. and analyzed by ELISA. Blue, male donors (A–E); red, female donors (F–J); red and blue data points indicate challenges with 1 × 106 CFU/mL S. pneumoniae. The results are from 2 independent experiments with duplicates, presented as individ- ual dots with mean ± SD.

Article Snippet: In order to assess the efficacy of TLR antagonism in the adjunctive treatment of pneumococcal meningitis, WT mice (n = 10) were i.p. treated with a cocktail of ceftriaxone (100 mg/kg body weight), a neutralizing anti-TLR2 T2.5 antibody (30 mg/kg body weight; Hycult Biotech, HM1054) (25, 26), and CQ (50 mg/kg body weight; Sigma-Aldrich) (27, 28) 18 hours p.i. and examined 24 hours thereafter (42 hours p.i.).

Techniques: In Vitro, Infection, Sterility, Enzyme-linked Immunosorbent Assay